Our analyses indicated that a combination of inhibitors targeting SFKs, MEK, and NF‐κB pathways can surpass the efficacy of SFK/MEK dual inhibition in reducing the number of IM‐resistant cells and of the CML CD34+‐initiated colonies. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.